Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Bipolar-I Disorder with Mania (BALSAM-2)
NCT06951711Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing KarXT with Placebo (2 arms). Primary endpoint: Young Mania Rating Scale at 3 weeks. Started Jun 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06951711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951711.